Sarepta Therapeutics is surging 30.9% today following the release of positive early clinical data from its siRNA pipeline targeting FSHD1 and DM1. The company hosted a webcast at 8:30 am ET this morning to present these Phase 1/2 ascending dose results, which investors are viewing as a significant translational milestone for the firm's genetic medicine platform. This clinical catalyst is driving the stock higher as the market reacts to the successful demonstration of the company's precision medicine capabilities in these new therapeutic areas.
Click any event to see why SRPT moved that day
No significant catalyst events detected.